Brokerages Set QIAGEN N.V. (NYSE:QGEN) Target Price at $49.40

Shares of QIAGEN N.V. (NYSE:QGEN) have been assigned a consensus recommendation of “Hold” from the twelve analysts that are covering the company, Marketbeat reports. Nine research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $49.4008.

A number of research analysts recently commented on QGEN shares. Wall Street Zen lowered shares of QIAGEN from a “buy” rating to a “hold” rating in a research note on Saturday. UBS Group increased their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Barclays set a $53.00 target price on shares of QIAGEN and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Weiss Ratings restated a “hold (c+)” rating on shares of QIAGEN in a research report on Wednesday, October 8th. Finally, Cowen restated a “hold” rating on shares of QIAGEN in a research report on Thursday, August 7th.

QIAGEN Stock Up 1.0%

Shares of QGEN stock opened at $47.30 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm’s 50-day moving average is $47.05 and its 200-day moving average is $45.63. The stock has a market cap of $10.51 billion, a price-to-earnings ratio of 27.95, a PEG ratio of 2.46 and a beta of 0.66. QIAGEN has a 52-week low of $37.63 and a 52-week high of $51.88.

QIAGEN (NYSE:QGEN) last issued its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same period in the prior year, the firm earned $0.55 EPS. QIAGEN’s quarterly revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts predict that QIAGEN will post 2.26 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Wealth Enhancement Advisory Services LLC acquired a new position in shares of QIAGEN during the 4th quarter worth approximately $202,000. GAMMA Investing LLC boosted its position in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of QIAGEN by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock worth $716,000 after acquiring an additional 395 shares in the last quarter. Bank Pictet & Cie Europe AG acquired a new stake in shares of QIAGEN during the 1st quarter worth approximately $669,000. Finally, Blue Trust Inc. boosted its position in shares of QIAGEN by 30.5% during the 1st quarter. Blue Trust Inc. now owns 13,519 shares of the company’s stock worth $543,000 after acquiring an additional 3,157 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.